1 |
Fliers E, Bianco AC, Langouche L, et al. Thyroid function in critically ill patients[J]. Lancet Diabetes Endocrinol, 2015,3(10): 816-825.
|
2 |
Carter JN, Eastman CJ, Corcoran JM, et al. Effect of severe, chronic illness on thyroid function[J]. Lancet, 1974,304(7887): 971-974.
|
3 |
Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters[J]. Crit Care Medi, 1995,23(1): 78-83.
|
4 |
Støving RK. Anorexia nervosa and endocrinology: a clinical update[J]. Eur J Endocrinol, 2019,180(1): R9-R27.
|
5 |
Bradlow HL, Boyar RM, O'Connor J, et al. Hypothyroid-Like alterations in testosterone metabolism in anorexia nervosa[J]. J Clin Endocrinol Metab, 1976,43(3): 571-574.
|
6 |
Naeije R, Golstein J, Clumeck N, et al. A low T3 syndrome in diabetic ketoacidosis[J]. Clin Endocrinol, 1978,8(6): 467-472.
|
7 |
Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the "euthyroid sick syndrome" [J]. Endocr Rev, 1982,3(2): 164-217.
|
8 |
Chopra IJ. Euthyroid sick syndrome: is it a misnomer?[J]. J Clin Endocrinol Metab, 1997,82(2): 329-334.
|
9 |
Chopra IJ. Nonthyroidal illness syndrome or euthyroid sick syndrome?[J]. Endocr Pract, 1996,2(1): 45-52.
|
10 |
De Groot LJ. Dangerous dogmas in medicine: the nonthyroidal illness syndrome[J]. J Clin Endocrinol Metab, 1999,84(1): 151-164.
|
11 |
Arrojo E Drigo R, Bianco AC. Type 2 deiodinase at the crossroads of thyroid hormone action[J]. Int J Biochem Cell Biol, 2011,43(10): 1432-1441.
|
12 |
Kaptein EM, Robinson WJ, Grieb DA, et al. Peripheral serum thyroxine, triiodothyronine and reverse triiodothyronine kinetics in the low thyroxine state of acute nonthyroidal illnesses. A noncompartmental analysis[J]. J Clin Invest, 1982,69(3): 526-535.
|
13 |
Werneck de Castro JP, Fonseca TL, Ueta CB, et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine[J]. J ClinInvest, 2015,125(2): 769-781.
|
14 |
Holland FW 2nd, Brown PS Jr, Weintraub BD, et al. Cardiopulmonary bypass and thyroid function: a "euthyroid sick syndrome" [J]. Ann Thorac Surg, 1991,52(1): 46-50.
|
15 |
Klemperer JD, Klein I, Gomez M, et al. Thyroid hormone treatment after coronary-artery bypass surgery[J]. N Engl J Med, 1995,333(23): 1522-1527.
|
16 |
王怀斌,甄文俊,佟宏峰,等. 冠状动脉旁路移植手术方式对甲状腺激素代谢的影响[J]. 中华心胸外科杂志,2007,4(1): 245-248.
|
17 |
Cerillo AG, Sabatino L, Bevilacqua S, et al. Nonthyroidal illness syndrome in off-pump coronary artery bypass grafting[J]. Ann Thorac Surg, 2003,75(1): 82-87.
|
18 |
Cerillo AG, Storti S, Mariani M, et al. The non-thyroidal illness syndrome after coronary artery bypass grafting: a 6-month follow-up study[J]. Clin Chem Lab Med, 2005,43(3): 289-293.
|
19 |
Ranasinghe AM, Bonser RS. Thyroid hormone in cardiac surgery[J]. Vascul Pharmacol, 2010,52(3-4): 131-137.
|
20 |
Choi YS, Shim JK, Song JW, et al. Efficacy of perioperative oral triiodothyronine replacement therapy in patients undergoing off-pump coronary artery bypass grafting[J]. J Cardiothorac Vascul Anesth, 2013,27(6): 1218-1223.
|
21 |
Farwell AP. Thyroid hormone therapy is not indicated in the majority of patients with the sick euthyroid syndrome[J]. Endocr Pract, 2008,14(9): 1180-1187.
|
22 |
Magalhães AP, Gus M, Silva LB, et al. Oral triiodothyronine for the prevention of thyroid hormone reduction in adult valvular cardiac surgery[J]. Braz J Med Biol Res, 2006,39: 969-978.
|
23 |
Spratt DI, Frohnauer M, Cyr-Alves H, et al. Physiological effects of nonthyroidal illness syndrome in patients after cardiac surgery[J]. Am J Physiol Endocrinol Metab, 2007,293(1): E310-E315.
|
24 |
Mainwaring RD, Lamberti JJ, Billman GF, et al. Suppression of the pituitary thyroid axis after cardiopulmonary bypass in the neonate[J]. Ann Thorac Surg, 1994,58(4): 1078-1082.
|
25 |
Murzi B, Iervasi G, Masini S, et al. Thyroid hormones homeostasis in pediatric patients during and after cardiopulmonary bypass[J]. Ann Thorac Surg, 1995,59(2): 481-485.
|
26 |
Yu D, Zou L, Cun Y, et al. Preoperative thyroid hormone levels predict ICU mortality after cardiopulmonary bypass in congenital heart disease patients younger than 3 months old[J]. BMC Pediatr, 2021, 21(1):50.
|
27 |
Bettendorf M, Schmidt KG, Grulich-Henn J, et al. Tri-iodothyronine treatment in children after cardiac surgery: a double-blind, randomised, placebo-controlled study[J]. Lancet, 2000,356(9229): 529-534.
|
28 |
Marwali EM, Boom CE, Budiwardhana N, et al. Oral triiodothyronine for infants and children undergoing cardiopulmonary bypass[J]. Ann Thorac Surg, 2017,104(2): 688-695.
|
29 |
Chowdhury D, Ojamaa K, Parnell VA, et al. A prospective randomized clinical study of thyroid hormone treatment after operations for complex congenital heart disease[J]. J Thorac Cardiovasc Surg, 2001,122(5): 1023-1025.
|
30 |
Mackie AS, Booth KL, Newburger JW, et al. A randomized, double-blind, placebo-controlled pilot trial of triiodothyronine in neonatal heart surgery[J]. J Thorac Cardiovasc Surg, 2005,130(3): 810-816.
|
31 |
Portman MA, Slee A, Olson AK, et al. Triiodothyronine supplementation in infants and children undergoing cardiopulmonary bypass (TRICC): a multicenter placebo-controlled randomized trial: age analysis.pdf[J]. Circulation, 2010,122(11 Suppl): S224-S233.
|
32 |
Zhang JQ, Yang QY, Xue FS, et al. Preoperative oral thyroid hormones to prevent euthyroid sick syndrome and attenuate myocardial ischemia-reperfusion injury after cardiac surgery with cardiopulmonary bypass in children: A randomized, double-blind, placebo-controlled trial[J]. Medicine, 2018,97(36): e12100.
|
33 |
王为民,崔传玉,郭士勇,等. 外源性甲状腺素对婴幼儿心脏手术围术期血流动力的影响[J]. 临床小儿外科杂志,2007,6(3): 13-14.
|
34 |
Mitchell JE, Hellkamp AS, Mark DB, et al. Thyroid function in heart failure and impact on mortality[J]. JACC Heart Fail, 2013,1(1): 48-55.
|
35 |
Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure[J]. Circulation, 2010,122(4): 385-393.
|
36 |
Danzi S, Klein I. Thyroid abnormalities in heart failure[J]. Heart Fail Clin, 2020,16(1): 1-9.
|
37 |
张璇,王文尧,杨敏,等. 心脏移植患者基础甲状腺激素水平对其预后的影响[J]. 中国循环杂志,2015,30(12): 1173-1177.
|
38 |
Wei J, Zhou Y. Association of thyroid-stimulating hormone (TSH) levels with the prognosis of patients undergoing heart transplantation: A retrospective study[J]. Front Cardiovasc Med, 2021, 8:720922.
|
39 |
Kowalczuk-Wieteska A, Baranska-Kosakowska A, Zakliczynski M, et al. Do thyroid disorders affect the postoperative course of patients in the early post-heart transplant period?[J]. Ann Transplant, 2011,16(3): 77-81.
|
40 |
Nagy Á, Holndonner-Kirst E, Eke C, et al. Perioperative low tetraiodothyronine levels and adverse outcomes after heart transplantation: A retrospective, observational study[J]. J Cardiothorac Vasc Anesth, 2020,34(10): 2648-2654.
|
41 |
Novitzky D, Cooper DK, Rosendale JD, et al. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies[J]. Transplantation, 2006,82(11): 1396-1401.
|
42 |
Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function[J]. Transplantation, 2003,75(8): 1336-1341.
|
43 |
Novitzky D, Mi Z, Collins JF, et al. Increased procurement of thoracic donor organs after thyroid hormone therapy[J]. Semin Thorac Cardiovasc Surg, 2015,27(2): 123-132.
|
44 |
Copeland H, Hayanga JWA, Neyrinck A, et al. Donor heart and lung procurement: A consensus statement[J]. J Heart Lung Transplant, 2020,39(6): 501-517.
|
45 |
Swanson EA, Adams T, Patel MS, et al. Impact of deceased donor management on donor heart use and recipient graft survival[J]. J Am Coll Surg, 2020, 231(3): 351-360.
|
46 |
Nagy Á, Szécsi B, Eke C, et al. Endocrine management and hormone replacement therapy in cardiac donor management: A retrospective observational study[J]. Transplant Proc, 2021, 53(10): 2807-2815.
|
47 |
Peled Y, Lavee J, Kassif Y, et al. Donor thyroid hormone therapy is associated with an increased risk of graft dysfunction after heart transplantation[J]. Clin Transplant, 2020,34(7): e13887.
|
48 |
Peled Y, Ram E, Klempfner R, et al. Donor thyroid hormone therapy and heart transplantation outcomes: ISHLT transplant registry analysis[J]. J Heart Lung Transplant, 2020,39(10): 1070-1078.
|
49 |
Lander MM. Thyroid hormone in cardiac transplantation: Cat chasing its tail?[J]. J Heart Lung Transplant, 2020,39(10): 1079-1080.
|
50 |
Holndonner-Kirst E, Nagy A, Czobor NR, et al. The impact of l-thyroxine treatment of donors and recipients on postoperative outcomes after heart transplantation[J]. JCardiothorac Vasc Anesth, 2019,33(6): 1629-1635.
|